SCHEMBL3578299

SCHEMBL3578299

Nc1cccc(C(=O)c2ccc3c(c2)NC(=O)C3=CNc2ccc(N3CCOCC3)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.46
PDGFRB P09619 2/20 0.43
ERBB2 P04626 1/20 0.41
RET P07949 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
MAPK14 Q16539 1/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
ALOX12 P18054 1/20 0.39
AURKB Q96GD4 2/20 0.38
KMO O15229 1/20 0.38
CHEK1 O14757 5/20 0.38
IKBKB O14920 1/20 0.38
CHEK2 O96017 1/20 0.38
KIT P10721 1/20 0.38
MARK3 P27448 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT1 P31749 1/20 0.38
MARK2 Q7KZI7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569089 0.93 PDGFRB (0.43) CSF1RPDGFRBERBB2RETSMN1; SMN2
SCHEMBL3578295 0.92 CSF1R (0.47) CSF1RPDGFRBERBB2RETSMN1; SMN2
SCHEMBL3573947 0.92 CSF1R (0.48) CSF1RPDGFRBERBB2RETSMN1; SMN2
SCHEMBL3583080 0.90 CSF1R (0.47) CSF1RSMN1; SMN2NPC1MAPK14MAPT
SCHEMBL3575776 0.90 NTRK1 (0.43) CSF1RERBB2AURKBPIM1
SCHEMBL3573943 0.89 CSF1R (0.49) CSF1RPDGFRBERBB2RETSMN1; SMN2
SCHEMBL3572999 0.87 CSF1R (0.48) CSF1RPDGFRBRETSMN1; SMN2NPC1
SCHEMBL3572998 0.87 CSF1R (0.48) CSF1RPDGFRBRETSMN1; SMN2NPC1
SCHEMBL3567940 0.87 AKT2 (0.42) PDGFRBCHEK1
SCHEMBL3569087 0.86 PDGFRB (0.43) CSF1RPDGFRBERBB2RETMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 CSF1R 776/4885PDGFRB 368/4885ERBB2 6/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 CSF1R 877/4885PDGFRB 407/4885ERBB2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.